Bloomberg News

Orexo Falls as Much as 20% After J&J Drug Research Deal Canceled

January 31, 2012

Jan. 31 (Bloomberg) -- Orexo AB fell as much as 20 percent, the most since November 2005, in Stockholm trading after saying drug research and licensing deals with Johnson & Johnson subsidiaries had been terminated. The shares traded down 4.1 kronor, or 15 percent, to 23.80 kronor at 9:15 a.m.

To contact the editor responsible for this story: Naomi Kresge at nkresge@bloomberg.net


Burger King's Young Buns
LIMITED-TIME OFFER SUBSCRIBE NOW

(enter your email)
(enter up to 5 email addresses, separated by commas)

Max 250 characters

 
blog comments powered by Disqus